In conjunction, liver damage was detected in 67.8% (n = 116/171) of patients with altered BMPs or assuming that those without risk for NASH did not have liver damage in 23% (116/505) of the study population. This evidence concerns the gene CLN5 and metabolic dysfunction-associated steatohepatitis.